Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

493
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
493
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

791
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
791
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

573
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart failure with mildly reduced ejection fraction (HFmrEF): where are we now?

Heart failure reviews·2026
Same author

Precision Medicine for Anticoagulation Strategies in the Cath Lab: Part 1.

Current cardiology reports·2026
Same author

Clinical Updates in Pulmonary Hypertension.

Reviews in cardiovascular medicine·2026
Same author

Current Advances and Navigating the Complexities of SVG-PCI.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same author

Financial Toxicity: Inequities and Impact on Cardiovascular Disease.

Arteriosclerosis, thrombosis, and vascular biology·2026

Related Experiment Video

Updated: Jun 26, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.4K

Role of Colchicine in Cardiovascular Disorders.

Errol Moras1, Lakshmi Subramanian2, Francisco Romeo3

  • 1From the Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Cardiology in Review
|May 16, 2024
PubMed
Summary

Low-dose colchicine shows promise as a targeted anti-inflammatory therapy for cardiovascular disease, reducing major adverse cardiovascular events. Careful monitoring of side effects and drug interactions is crucial for safe and effective use in patients.

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

825
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Related Experiment Videos

Last Updated: Jun 26, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.4K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

825
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Inflammation Research

Background:

  • Inflammation is a key driver of atherosclerosis and cardiovascular diseases.
  • Colchicine, traditionally used for gout, is now recognized for its anti-inflammatory cardiovascular benefits.
  • Residual inflammatory risk remains a challenge in cardiovascular disease management.

Purpose of the Study:

  • To review the mechanisms of action, targets, and pharmacokinetics of colchicine in cardiovascular conditions.
  • To summarize the evidence on the safety and efficacy of colchicine for cardiovascular disorders.
  • To highlight colchicine as a novel, targeted anti-inflammatory therapy for cardiovascular disease.

Main Methods:

  • Comprehensive literature review of landmark trials and clinical studies.
  • Analysis of colchicine's molecular and biochemical targets in cardiovascular disease.
  • Evaluation of pharmacokinetic data and safety profiles, including adverse effects and drug interactions.

Main Results:

  • Landmark trials demonstrate that low-dose colchicine reduces major adverse cardiovascular events when added to standard therapies.
  • Colchicine effectively targets both traditional risk factors and residual inflammatory risk.
  • Major cardiovascular societies endorse colchicine as a first-line targeted anti-inflammatory therapy.

Conclusions:

  • Colchicine represents a new era in cardiovascular prevention and treatment.
  • Its efficacy and safety in conditions like coronary artery disease, pericarditis, atrial fibrillation, and heart failure are supported by robust evidence.
  • Close monitoring for potential adverse effects and drug interactions is essential for optimizing colchicine therapy.